11/9/2022 1:03:10 PM
Hoth Therapeutics Regains Compliance With Nasdaq Listing Requirements
10/31/2022 10:01:42 AM
Hoth Reports Positive Biolexa Phase 1b Clinical Trial Results In Mild To Moderate Atopic Dermatitis; Stock Up
9/20/2022 9:08:31 AM
Hoth Therapeutics Partners With Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury And Stroke
9/6/2022 8:23:57 AM
Hoth MRNA Frame-Shifting Therapeutic, HT-004, Shows Potential To Reduce Lung Inflammation In Asthma & Allergy Disorders
7/12/2022 10:35:03 AM
Hoth Therapeutics Reports HT-ALZ Therapeutic Shows Cognitive Improvements In Alzheimer's Disease Mouse Model
6/9/2022 8:21:01 AM
Hoth Therapeutics Announces Extension Of Washington University Alzheimer's Mouse Model Study With HT-ALZ
5/3/2022 8:16:31 AM
Hoth:Preliminary Efficacy Findings From Phase 1b Trial Of BioLexa Lotion Shows Improvement In Atopic Dermatitis Symptoms
4/11/2022 11:42:41 PM
Hoth Therapeutics Announces Pricing Of 8.23 Mln Shares At $0.85/Shr, Priced At-the-market
3/22/2022 9:51:09 AM
Hoth Therapeutics Says Successfully Completed Manufacturing Feasibility Of The HT-KIT Drug Substance
3/11/2022 8:05:40 AM
Hoth Therapeutics : FDA Grants Orphan Drug Designation To Cancer Therapeutic HT-KIT To Treat Mastocytosis
2/7/2022 8:13:05 AM
Hoth Therapeutics Announces Presentation Of HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data
1/31/2022 8:18:51 AM
Hoth Appoints John Cirrito And Carla Yuede To Scientific Advisory Board
1/4/2022 8:09:00 AM
Hoth Reports HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid ? In Alzheimer's Disease; Stock Up